EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Open-label treatment extension of ruxolitinib cream in vitiligo: findings from the Topical Ruxolitinib Evaluation in Vitiligo (TRuE-V) long-term extension phase III study

John E Harris, Kim Papp iD, Khaled Ezzedine, Michael Sebastian, Amit G Pandya, Julien Seneschal, Mark Amster, Maryam Shayesteh Alam, Seth B Forman, Jacek Zdybski, Anthony Nuara, Deanna Kornacki und 3 weitere

British Journal of Dermatology · 18.02.2026 · 194 (3) · 591-593

DOI: 10.1093/bjd/ljaf485 ↗

Kurz gefasst

Fachartikel in der Zeitschrift British Journal of Dermatology, online erschienen am 17.12.2025. Verfasst von John E Harris und 14 weiteren Autor:innen. Beteiligte Einrichtung: University of Massachusetts Chan Medical School, Worcester, MA, USA. Die Arbeit wurde bisher 12-mal zitiert (Crossref) und nennt 4 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Incyte Corporation.

AbstractBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

We present data from the Topical Ruxolitinib Evaluation in Vitiligo (TRuE-V) long-term extension (LTE) study evaluating repigmentation outcomes with continued 1.5% ruxolitinib cream treatment in patients who did not achieve near-complete facial repigmentation in TRuE-V1/TRuE-V2. Among patients in the TRuE-V1/TRuE-V2 trials who applied ruxolitinib cream from day 1, approximately 66% achieved F-VASI 75 (indicative of treatment success) at week 104, increasing from nearly 31% at week 52 (TRuE-V LTE baseline); similar repigmentation improvements were reported in patients who switched from vehicle to ruxolitinib cream after TRuE-V1/TRuE-V2 at week 24, albeit with lower overall response rates due to the shorter duration of ruxolitinib cream application. These findings indicate that continued ruxolitinib cream treatment allows further repigmentation in many patients.

Autor:innen und Institutionen

  • University of Massachusetts Chan Medical School, Worcester, MA, USA.

ORCID-Profile: Kim Papp, Thierry Passeron

Förderung

  • Incyte Corporation

Zitieren

APA

Harris, J. E., Papp, K., Ezzedine, K., Sebastian, M., Pandya, A. G., Seneschal, J., Amster, M., Shayesteh Alam, M., Forman, S. B., Zdybski, J., Nuara, A., Kornacki, D., Wei, S., Passeron, T., & Rosmarin, D. (2026). Open-label treatment extension of ruxolitinib cream in vitiligo: findings from the Topical Ruxolitinib Evaluation in Vitiligo (TRuE-V) long-term extension phase III study. British Journal of Dermatology, 194(3), 591-593. https://doi.org/10.1093/bjd/ljaf485

Vancouver

Harris JE, Papp K, Ezzedine K, Sebastian M, Pandya AG, Seneschal J, et al. Open-label treatment extension of ruxolitinib cream in vitiligo: findings from the Topical Ruxolitinib Evaluation in Vitiligo (TRuE-V) long-term extension phase III study. British Journal of Dermatology. 2026;194(3):591-593. doi:10.1093/bjd/ljaf485

BibTeX
@article{Harris2026,
  author = {Harris, John E and Papp, Kim and Ezzedine, Khaled and Sebastian, Michael and Pandya, Amit G and Seneschal, Julien and Amster, Mark and Shayesteh Alam, Maryam and Forman, Seth B and Zdybski, Jacek and Nuara, Anthony and Kornacki, Deanna and Wei, Shaoceng and Passeron, Thierry and Rosmarin, David},
  title = {Open-label treatment extension of ruxolitinib cream in vitiligo: findings from the Topical Ruxolitinib Evaluation in Vitiligo (TRuE-V) long-term extension phase III study},
  journal = {British Journal of Dermatology},
  year = {2026},
  volume = {194},
  number = {3},
  pages = {591--593},
  doi = {10.1093/bjd/ljaf485}
}
Kostenlos starten →